Patients with hormone receptor positive HER2 negative locally advanced or metastatic breast cancer
Conditions
Brief summary
The primary endpoint of this trial is progression-free survival (PFS). PFS time is measured from trial registration until the date of investigator-determined objective progression as defined by RECIST v1.1, or death from any cause. Patients who have neither progressed nor died will be censored at the day of their last radiographic tumor assessment, if available, or date of trial registration if no post-initiation (that is, post-baseline) radiographic assessment is available.
Detailed description
Overall Survival (OS), Objective Response Rate (ORR), Clinical Benefit Rate (CBR)
Interventions
Sponsors
Universitaetsklinikum Ulm AöR
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint of this trial is progression-free survival (PFS). PFS time is measured from trial registration until the date of investigator-determined objective progression as defined by RECIST v1.1, or death from any cause. Patients who have neither progressed nor died will be censored at the day of their last radiographic tumor assessment, if available, or date of trial registration if no post-initiation (that is, post-baseline) radiographic assessment is available. | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival (OS), Objective Response Rate (ORR), Clinical Benefit Rate (CBR) | — |
Countries
Germany
Outcome results
None listed